文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide.

作者信息

Schade Sebastian, Mollenhauer Brit, Trenkwalder Claudia

机构信息

Department of Clinical Neurophysiology University Medical Center Göttingen Göttingen Germany.

Paracelsus-Elena-Klinik Klinikstr. 16, 34128 Kassel Germany.

出版信息

Mov Disord Clin Pract. 2020 Mar 16;7(3):343-345. doi: 10.1002/mdc3.12921. eCollection 2020 Apr.

DOI:10.1002/mdc3.12921
PMID:32258239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7111582/
Abstract
摘要

相似文献

[1]
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide.

Mov Disord Clin Pract. 2020-3-16

[2]
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.

Acta Neurol Scand. 2019-4-22

[3]
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

Lancet Neurol. 2015-12-23

[4]
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.

J Parkinsons Dis. 2015

[5]
Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.

Neuropharmacology. 2013-10-19

[6]
Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.

Br J Pharmacol. 2015-4

[7]
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.

J Parkinsons Dis. 2016

[8]
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.

Neurology. 2018-4-25

[9]
Real life evaluation of safinamide effectiveness in Parkinson's disease.

Neurol Sci. 2018-2-13

[10]
Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.

Neurodegener Dis Manag. 2018-10

引用本文的文献

[1]
Exploring the relationship between orthostatic hypotension and gait in people with Parkinson's disease.

Clin Auton Res. 2025-9-6

[2]
Quantitative analysis of gait parameters in Parkinson's disease and the clinical significance.

Front Neurol. 2025-8-20

[3]
Comparative study of autonomic dysfunction between Parkinson's disease with LRRK2, PRKN, and GBA mutations.

Front Neurol. 2025-8-19

[4]
Parkinson's disease medication adjustments based on wearable device information compared to other methods: randomized clinical trial.

NPJ Parkinsons Dis. 2025-8-20

[5]
Early parkinson's disease: levodopa requirements are associated with the striatal DaT-uptake.

J Neural Transm (Vienna). 2025-8-16

[6]
CSF phospho-tau levels at Parkinson's disease onset predict the risk for development of motor complications.

J Neurol. 2025-8-13

[7]
Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson's Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose.

Brain Sci. 2025-6-20

[8]
Detecting delirium in Parkinson's disease: an evaluation of diagnostic accuracy of bedside tools.

Age Ageing. 2025-7-1

[9]
Transformer-based long-term predictor of subthalamic beta activity in Parkinson's disease.

NPJ Parkinsons Dis. 2025-7-12

[10]
Rotigotine Patch is Effective for Levodopa (L-Dopa)-Induced Dyspnea: A Case Report.

Cureus. 2025-6-2

本文引用的文献

[1]
Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.

Eur J Neurol. 2019-3-25

[2]
Safinamide: an add-on treatment for managing Parkinson's disease.

Clin Pharmacol. 2018-4-5

[3]
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.

J Parkinsons Dis. 2018

[4]
Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.

Neurol Clin Pract. 2017-2

[5]
Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

Mov Disord. 2010-11-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索